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Abstract 
Atrial fibrillation is one of the major cardiovascular health problems: It is a common, chronic 
condition, affecting 2-3% of the populations in Europe and the USA and requiring 1-3% of health care 
expenditure due to stroke, sudden death, heart failure, unplanned hospitalizations, and other 
complications. Early diagnosis of AF, ideally before the first complication occurs, remains a 
challenge, illustrated by patients who are only diagnosed with AF when hospitalized for acute 
cardiac decompensation or stroke. Once diagnosed, AF requires chronic, multidimensional 
management in five domains (acute management, treatment of underlying and concomitant 
cardiovascular conditions, stroke prevention therapy, rate control, and rhythm control). Providing 
these treatment options consistently to all AF patients remains challenging, despite recent 
improvements. Integrated care models providing patient-centred care in or close to the community 
while maintaining access to all specialist treatment options emerge as the best approach to achieve 
consistent delivery of these chronic treatments to all AF patients in need of better management. 
Ongoing research efforts will determine when to initiate oral anticoagulation in patients with device-
detected atrial high rate episodes, quantify the prognostic impact of early and comprehensive 
rhythm control therapy including AF ablation, and delineate optimal methods to reduce bleeding 
complications in anticoagulated AF patients. In addition, research efforts are needed to define 
different types of AF based on the main causes of AF in a given patient to pave the way for the 
clinical development of stratified AF therapy. 
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The atrial fibrillation epidemic. Atrial fibrillation (AF) affects 2-3% of the populations in Europe 1-3, 
and more than 1% of the entire health care expenditure is spent on AF management. 4,5 Less than 
one in 200 persons below 50 years of age, but more than one in ten in populations aged 80 or above 
suffer from AF. 1-3 Thirteen to 21 percent of the populations in Europe are aged 65 years or older 
today (http://data.org/search.aspx?q=age), and we enjoy ever longer lives. The projected population 
ageing, combined with an accumulation of chronic non-communicable cardiovascular diseases and 
risk factors 6, will lead to a dramatic increase of AF patients in the coming years. This AF epidemic 
and the severe complications associated with AF (Table 1A) render atrial fibrillation one of the major 
threats to cardiovascular health. 7 
Table 1A: Common symptoms and complications of atrial fibrillation. Silent AF that does not cause 
symptoms but still leads to complications is not uncommon. Treatment can prevent many, but not all 
AF-related complications. Most symptoms and consequences of AF are interrelated and thus 
complications and symptoms can link across lines in this table. 
Symptoms of AF Related complication of AF Treatment to prevent symptoms and 
complications 
- Stroke Treatment of underlying conditions, oral 
anticoagulation, possibly left atrial 
appendage occluders 
Fatigue or tiredness Depression, reduced quality 
of life 
? (possibly rhythm control) 
Shortness of Breath Impaired autonomy, 
worsening of cardiac 
function, unplanned 
hospitalizations 
ACE inhibitors, rate control, possibly 
rhythm control 
Palpitations Tachycardiomyopathy, 
reduced autonomy 
Rate control, rhythm control, possibly 
anticoagulation 
Chest pain Acute coronary syndrome, 
unplanned hospitalizations 
Treatment of underlying conditions, 
possibly anticoagulation 
Depressed mood, 
anxiety 
Frequent hospitalizations, 
Impaired cognitive function 
Possibly rate control and rhythm control 
Possibly oral anticoagulation 
 
Table 1B: The modified EHRA symptoms scale (mEHRA scale) to describe severity of AF-related 
symptoms in a semi-quantitative fashion. Modified from Wynn et al8 and recommended for use by 
the European Society of Cardiology. 2 
mEHRA scale Symptoms Description 
1 None AF does not cause any symptoms (includes silent AF) 
2a Mild Normal daily activity not affected by symptoms related to 
AFa 
2b Moderate Normal daily activity not affected, but patient troubled by 
symptomsa 
3 Severe Normal daily activity affected by AF 
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4 Disabling Normal daily activity discontinued due to AF 
AF = atrial fibrillation; EHRA = European Heart Rhythm Association. 
 
Clinical presentation and AF-related symptoms. AF is a common cause of ischemic stroke. 2 In AF 
patients on oral anticoagulation, stroke is relatively infrequent (1.5% per year in trials) 9,10, but 
worsening of heart failure and sudden death remain common even in adequately treated AF 
patients. 11,12 Common symptoms in AF patients are fatigue or shortness of breath, as well as 
palpitations 13-18, but also anxiety 19 and a depressed mood. 20-23 These symptoms may be especially 
pronounced during the initial presentation. Furthermore, stroke, heart failure, or even sudden death 
can constitute the initial presentation of AF patients. Sudden death can be a consequence of 
underlying cardiac diseases, e.g. inherited cardiomyopathies 24,25 or heart failure 26 , but may also be 
a consequence of the irregular ventricular activation pattern in AF. Every 4th to 5th AF patient is 
admitted to hospital in a year. 14,16,27,28 Hospitalizations are most commonly triggered by 
symptomatic AF, but also reflect that AF patients often suffer other cardiovascular conditions that 
require in-patient therapy.  
Importantly, many patients do not experience any AF-related symptoms (“silent AF”), and a stroke 
may be the first presentation of AF. 29,30 Silent AF is common: When systematic ECG monitoring is 
applied to patients with symptomatic AF, around 70% of AF episodes are silent. 31 Patients with 
silent AF are still at risk of stroke, heart failure or sudden death, illustrating the public health 
importance of detecting silent AF. 32,33 
ECG screening in populations to diagnose silent AF. Unfortunately, AF is often not diagnosed before 
the first stroke: Approximately 5% of unselected patients admitted to stroke units present with overt 
(usually chronic) AF on admission. 29 Detecting AF prior to the first stroke should therefore be a 
public and individual health priority. “Opportunistic” screening for AF, i.e. pulse palpation followed 
by ECG in those with an irregular pulse 35, is recommended by AF guidelines in all patients aged 65 or 
more. 2,36 Initial experience with systematic ECG screening in elderly populations using patient-
operated devices seems promising 32,37, but more research is needed before population-wide ECG 
screening can be recommended.  
ECG screening in stroke survivors. ECG screening for silent AF has been extensively evaluated in 
survivors of a stroke or transient ischemic attack. ECG monitoring for a few days identifies silent AF 
in an additional 5% of unselected patients admitted to stroke units. 29,38 Longer ECG monitoring 
identifies even more patients with AF (5 – 25% additional yield) 29,30,39, especially in patients with 
“cryptogenic stroke” 38,40,41 or “embolic stroke of unknown source” (ESUS). 42 ECG monitoring for at 
least 72 hours is recommended in stroke survivors and in at-risk populations. 2 Recently, one of the 
first randomized studies confirmed that longer ECG monitoring results in a higher detection rate of 
AF in stroke survivors (13.5% vs. 4.5%). 43 Ongoing studies evaluate the effect of ECG screening in 
stroke survivors on uptake of anticoagulation and prevention of strokes. 44 Based on the high 
prevalence of silent AF, ongoing trials evaluate whether oral anticoagulation should be used in all 
patients with an embolic stroke of unknown etiology, irrespective of heart rhythm. 45,46  
Management of patients with AF detected by ECG screening. Detection of silent AF has immediate 
consequences for antithrombotic therapy: Most patients with incidentally diagnosed AF, or with AF 
detected by systematic ECG screening, will have stroke risk factors that render them eligible for oral 
anticoagulation. 2,32,35  Patients with silent AF should also be investigated for concomitant 
cardiovascular conditions that require therapy. 2 Rhythm control therapy is not required in patients 
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with silent AF, unless they develop AF symptoms. Periodic reassessment for symptoms and 
complications of AF is advisable.  
Management of patients with atrial high episodes detected by implanted devices. Importantly, all 
AF therapies have been evaluated in patients with ECG-documented AF. Thus, atrial arrhythmias 
detected by other methods, e.g. an irregular pulse detected by blood pressure machines or by an 
optical device, or atrial high rate episodes (AHRE) detected by a pacemaker, require verification of 
AF by ECG before initiating AF therapy. 2 Importantly, not all atrial AHRE detected by implanted 
devices are AF. 47,48 Furthermore, there is good data to show that the stroke risk is lower in patients 
with AHRE, but without ECG-documented AF, than in patients with AF. Consequently, we cannot 
know whether patients with AHRE benefit from oral anticoagulation. Ongoing controlled trials such 
as ARTESiA (NCT01938248) and NOAH – AFNET 6 (NCT02618577) currently evaluate the benefit and 
risk of oral anticoagulation in patients with atrial high rate episodes.  
 
The five domains of atrial fibrillation management. 
Atrial fibrillation requires attention to five domains of management, where each treatment 
component targets different components of the heart (Figure 1). These five domains of AF 
management are: Acute stabilization of patients who present with AF complications or 
hemodynamic compromise, detection and treatment of underlying and accompanying 
cardiovascular conditions, stroke risk assessment and in most patients oral anticoagulation for 
stroke prevention, rate control, and rhythm control therapy in symptomatic patients (Figure 2). 
Acute stabilization, treatment of concomitant conditions, and stroke prevention carry prognostic 
benefits. Rate control and rhythm control therapy can help to maintain left ventricular function but 
are mainly used to improve AF-related symptoms. All domains have the potential to maintain 
functional integrity of the heart (Figure 1). 
 
Detection and management of concomitant cardiovascular conditions: Hypertension, heart failure, 
valvular heart disease, diabetes, coronary and other arterial vascular disease, and others 
The presence of atrial fibrillation should be taken as a strong suggestion that other cardiovascular 
conditions are present. To detect such conditions, a careful cardiovascular examination and an 
echocardiogram should be performed in all AF patients at the time of diagnosis. Comprehensive 
diagnosis and treatment of cardiovascular risk factors and concomitant diseases 51 should be an 
integral part of AF management. 
Hypertension is common in AF patients. Adequate control of blood pressure reduces stroke risk, 
bleeding risk on anticoagulation, and probably recurrences of AF. ACE inhibitors and sartans appear 
to prevent AF slightly better than other hypertensive agents, especially in patients with left 
ventricular hypertrophy or heart failure, 52,53 but by and large antihypertensive agents can be used as 
recommended for hypertensive patients in general.  
Heart failure and AF often coexist. 54 The management of patients with AF and heart failure requires 
simultaneous treatment of both AF 2 and heart failure 55, including acute control of rate and urgent 
cardioversion in hemodynamically compromised patients, diuretic therapy in patients with fluid 
overload, initiation of anticoagulation, and inhibition of the renin-angiotensin-aldosterone system. 56 
Beta blockers can be safely used, but their prognostic benefit seems lost in patients with AF and 
heart failure. 57 It is often difficult to distinguish symptoms of heart failure from AF symptoms in the 
Paulus Kirchhof: Atrial fibrillation (clinical seminar) page 6 
acute setting, especially in patients with preserved or moderately impaired ejection fraction. A 
careful reconstruction of symptoms and disease signs over time often helps, and occasionally 
restoration of sinus rhythm is useful to distinguish AF-related symptoms from heart failure. 
Valvular heart disease, especially mitral or aortic valve disease, can become more symptomatic 
when AF develops. New onset AF is regarded as a sign for progressive atrial damage, and is one of 
the factors that should be considered to determine the best time point for valve surgery. Patients 
with rheumatic heart disease 2 have not been tested in the NOAC trials programmes. Patients with 
mechanical heart valves 58 require vitamin K antagonists for oral anticoagulation. 
Obesity contributes to recurrent AF, possibly via activation of adipocytes in the atria and/or by fatty 
infiltration of atrial myocardium. 59,60 Weight reduction and increased general fitness help to prevent 
AF in obese patients, and can even obviate the need for catheter ablation. 61-63  
Coronary artery disease can be managed with an anticoagulant without further antiplatelet therapy 
in stable patients. After stenting or an acute coronary syndrome, the added bleeding risk of 
combined antiplatelet and anticoagulant therapy needs to be balanced against the need to prevent 
recurrent thrombo-embolic events. Usually, this can be achieved by short-term combination therapy 
for 1-12 months, currently consisting of an anticoagulant, clopidogrel, and probably aspirin. 2,64-66 
Ongoing studies will inform about the safety of other combination therapies with non-vitamin K 
antagonist oral anticoagulants and newer antiplatelet agents. 67 Most other treatments for coronary 
artery disease can readily be combined with AF therapy. 
 
Oral anticoagulation for stroke prevention.  
The combination of a local prothrombotic milieu in the left atrium, systemic activation of 
coagulation, blood stasis in the atria, and expression of prothrombotic factors on the atrial 
endothelium all contribute to clot formation in patients with atrial fibrillation.68-70 The annual stroke 
risk in non-anticoagulated AF patients is between <1% and >10%.69,70 Oral anticoagulation therapy 
with vitamin K antagonists or non-vitamin K antagonist oral anticoagulants (NOACs) prevents most 
ischemic strokes in patients with atrial fibrillation at risk for stroke, translating into preserved 
independence and autonomy for patients, lower morbidity, and longer lives in AF patients at high 
stroke risk. 9,10  Antiplatelet therapy does not prevent strokes in AF patients. AF patients with two or 
more clinical stroke risk factors (Table 2A) benefit from oral anticoagulation, especially those at 
higher age (e.g. > 75 years) and survivors of a stroke, but also those with heart failure, hypertension, 
diabetes mellitus (especially when requiring insulin therapy), or vascular disease. Conversely, 
patients at low risk of stroke do not require antithrombotic therapy, i.e. those without clinical stroke 
risk factors, and some patients with one of the clinical stroke risk factors 2,71.  
Oral anticoagulation is not without side effects: Approximately 2% of anticoagulated AF patients 
experience a major bleeding event per year of exposure to anticoagulants. 72,73 Modifiable bleeding 
risk factors should therefore be reduced in all anticoagulated AF patients (Table 2B) to minimise 
bleeding. Many bleedings have a treatable cause, e.g. bleeding due to gastric ulcers or cerebral 
aneurysms, and such causes should be identified and treated promptly in AF patients in need for 
anticoagulation. Importantly, most patients with a high bleeding risk are also at high risk of stroke 
and will benefit from anticoagulation. 2 Recent data suggest that selected biomarkers, e.g. troponin, 
BNP, or markers of kidney disease, can be used to refine stroke risk estimation in selected patients, 
although further data are needed to inform their use in routine care. 2,74,75  
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Table 2A Clinical risk factors for stroke in patients with atrial fibrillation as validated in the 
CHA2DS2-VASc score for stroke risk estimation in patients with atrial fibrillation.  
Clinical stroke risk factor  Definition and explanation 
Congestive heart failure  
 
Signs or symptoms of heart failure or evidence of 
reduced left ventricular ejection fraction 
Hypertension  
 
Resting blood pressure > 140/90 mmHg on at least two 
occasions or current antihypertensive treatment 
Increasing age 
 
Stroke risk continuously increases with age. Most 
stroke risk scores define age strata (e.g. ≥ 65 years or ≥ 
75 years) to simplify stroke risk estimation 
Diabetes mellitus  
 
Fasting glucose > 125 mg/dL or treatment with 
hypoglycaemic agents, especially when patients 
require insulin for diabetes management 
Previous stroke, transient ischemic 
attack, or thromboembolism  
 
A prior stroke or transient ischemic attack, together 
with older age, is probably the strongest clinical stroke 
risk factor in patients with atrial fibrillation. 
Vascular disease  
 
Previous myocardial infarction, peripheral artery 
disease, or aortic plaque 
Female sex 
 
Female patients with AF appear to have a higher stroke 
risk than male patients when other risk factors are 
present. In patients with only one or two of the clinical 
stroke risk factors, female AF patients do not appear to 
have an increased stroke risk. 2,71 
CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke 
(doubled), Vascular disease, Age 65–74, and Sex (female).  
Table 2B: Modifiable bleeding risk factors in anticoagulated AF patients, their definition, and 
interventions to minimize these bleeding risk factors. Modifiable bleeding risk factors have been 
extracted from several validated bleeding risk scores. 2 
Modifiable bleeding risk 
factors  
Definition, explanation Proposed intervention 
Concomitant therapy 
with antiplatelet agents 
or nonsteroidal anti-
inflammatory 
medications 
 
Including over the counter medication 
and paracetamol. Selected patients, e.g. 
those requiring stenting or those at risk 
of a recurrent acute coronary syndrome, 
require short term combination therapy. 
Avoid co-medication, advise 
patients of risk 
Uncontrolled 
hypertension 
 
Blood pressure > 160/90 mmHg during 
office measurements, and uncontrolled 
blood pressure peaks 
Treat hypertension 
adequately 
Labile INR values in 
patients treated with 
vitamin K antagonists 
 
Most often measured as a low time in 
therapeutic range 
Control INR better 
(including self-
measurement), change to a 
NOAC 
Excess alcohol use Daily alcohol consumption, consumption 
of more than 65g – 110g of alcohol per 
week (8 - 14 units) 
Reduce alcohol 
consumption, provide 
access to behaviour 
changing programmes 
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Several oral anticoagulants are effective and approved for stroke prevention in AF. Four different 
vitamin K antagonists and four non-vitamin K antagonist oral anticoagulants (NOACs) are available 
and allow to select an appropriate oral anticoagulant in most patients with AF (Table 3). 2,76 Aspirin 
does not prevent ischemic stroke in AF patients. Of note, there is a tendency to prescribe lower 
doses of NOACs than those that were tested and approved in controlled trials, which seems 
associated with higher complication rates. 73 Oral anticoagulation can often be initiated by 
adequately trained general practitioners, especially when they form part of a larger network 
providing integrated AF care, and may be guided by IT tools to ensure appropriate selection of 
eligible patients for anticoagulation and for a specific dose of an anticoagulant. NOACs therapy is 
less likely to cause bleeding, especially intracranial hemorrhage, rendering them preferable over 
vitamin K antagonists in eligible patients. 10 In selected patients with true contraindications to any 
form of oral anticoagulation, interventional or surgical left atrial appendage occlusion can be 
considered as an alternative to oral anticoagulation. 77-81 Difficult anticoagulation decisions should be 
informed by a multidisciplinary AF Heart Team involving anticoagulation specialists, stroke 
neurologists, and experts in occluder therapy. 2  
Despite the proven benefits of oral anticoagulation in AF patients, many patients with AF at risk for 
stroke do not receive oral anticoagulation or discontinue oral anticoagulants soon after initiation. 82-
88 Major bleeding events, e.g. gastro-intestinal, hypertensive or intracranial bleeds, are one of the 
major reasons to discontinue oral anticoagulation. 82,84,89-92 A short interruption of anticoagulation is 
usually required to manage acute bleeding events. 2,76 Once the cause of bleeding has been 
eliminated (e.g. treatment of a gastric ulcer, clipping or coiling of an arterial malformation, 
optimization of antihypertensive therapy, see also Table 2B), oral anticoagulation should probably 
be reinitiated in most AF patients at risk for stroke. 93,94 Information of AF patients about their 
therapy, leading to patients who “own” and participate in AF management, has the potential to 
improve this situation. 95-97 To improve continuation of chronic therapy, integrated AF management 
models should be developed (see below).  
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Table 3: Oral anticoagulants and interventional stroke prevention treatment in AF patients.  
 Dose Dose reduction 
Vitamin K antagonists 
Warfarin typical dose 1 – 5 mg OD 
Individual dose aiming at an international 
normalized ration (INR) of 2-3 
Phenprocoumon typical dose 0.5 – 3 mg OD 
Fluindione typical dose 5 – 30 mg OD 
Acecoumarol  typical dose 2 – 4 mg OD 
Non-vitamin K antagonist oral anticoagulants 
Apixaban 5 mg BD 2.5 mg BD in patients fulfilling two of the 
following criteria: 
serum creatinine > 1.5 mg/dl, age 80 > 80 years, 
weight > 60 kg 
Apixaban has not been tested in patients with a 
baseline creatinine clearance < 25 ml/min. 
Dabigatran 110 mg BD 
150 mg BD 
In Europe, a dose of 110 mg BD is suggested in 
patients > 75 years of age* 
Dabigatran has not been tested in patients with a 
baseline creatinine clearance < 30 ml/min. 
Edoxaban 60 md OD 30 mg OD if creatinine clearance < 50 ml/min 
Edoxaban has not been tested in patients with a 
baseline creatinine clearance < 30 ml/min. 
Rivaroxaban 20 mg OD 15 mg OD if creatinine clearance is < 50 ml /min 
Rivaroxaban has not been tested in patients with 
a baseline creatinine clearance < 30 ml/min. 
Left atrial appendage occlusion 
Interventional left 
atrial appendage 
occlusion 
The interventional procedure carries a risk of complications (tamponade, 
stroke, vascular access complications). Several post-interventional 
antithrombotic therapy regimes have been evaluated. 
Surgical occlusion of 
the left atrial 
appendage 
Surgical atrial occlusion or exclusion does not add much to the risk of cardiac 
surgery when performed concomitant with open heart surgery. There is a small 
risk of bleeding and tamponade, and a risk of incomplete occlusion. 
*In the USA, dabigatran is not approved for stroke prevention in AF at the 110 mg BD dose. The FDA 
has also approved dabigatran 75 mg BD for stroke prevention in AF patients on dialysis. 
Rate control therapy. During atrial fibrillation, each part of the atrial myocardium is stimulated at a 
rate of 300 – 400 activations per minute. The rapid reactivation of atrial myocardium leads to atrial 
contractile standstill in most patients and results in rapid and irregular ventricular rates. Most 
symptomatic AF patients therefore present with high ventricular rates, and control of ventricular 
rate is used to improve left ventricular function and AF-related symptoms. Rate control is achieved 
using beta blockers, digoxin or digitoxin, and verapamil or diltiazem. The initial heart rate target can 
be lenient (ventricular rate at rest < 110 bpm 98). There is currently no evidence favouring stricter 
initial heart rate targets, and no clear evidence linking rate control therapy to better outcomes. 57,99 
Rather, current recommendations for rate control therapy are based on small studies with 
composite outcomes 98,100 and on the therapies evaluated in the rate control arms of the AFFIRM, 
RACE, and PIAF trials. 101-103 Details of rate control therapy approaches can be found in the 2016 ESC 
guidelines on AF 2 and in a recent seminar published in the Lancet. 104 Even on adequate rate-control 
therapy, many AF patients remain symptomatic, thus requiring adaptation of rate control therapy 
and/or rhythm control therapy on top of rate control (see next section).  
Rhythm control therapy. Restoring and maintaining sinus rhythm in AF patients can improve AF-
related symptoms. There is no sign so far that rhythm control therapy improves outcomes in AF 
patients. Cardioversion, antiarrhythmic drugs, and catheter or surgical AF ablation are available for 
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this type of therapy. Ongoing controlled studies such as CABANA (NCT00911508) and EAST – AFNET 
4 (www.easttrial.org 105) will determine whether modern rhythm control therapy (early therapy 
including the use of catheter ablation) can improve prognosis in AF patients when added to 
evidence-based anticoagulation and rate control therapy. The current approach to rhythm control 
therapy is summarized in the 2016 ESC AF guidelines 2 and has recently been reviewed in a seminar 
in the Lancet. 106 Importantly, rhythm control therapy will benefit from integration into a “holistic”, 
integrated approach to AF care that also provides treatment of underlying cardiovascular diseases 
and precipitating factors (e.g. obesity), continued stroke prevention and rate control therapy (see 
“integrated AF care” below). This will minimize AF recurrences and improve quality of life. 
Systematic symptom assessment, e.g. using the modified EHRA score (Table 1B), should guide the 
use of rhythm control therapy. Cardioversion, pharmacological or electrical 107-109, long-term 109,110 or 
targeted short-term 109,111  antiarrhythmic drug therapy, and catheter ablation are the main 
treatments to restore and maintain sinus rhythm. The choice of antiarrhythmic agent needs to 
consider concomitant cardiovascular conditions to minimize side effects. Abnormal prolongation of 
the QRS (by more than 25% of the baseline value 2,109) and QT (by more than 60 ms 2,110,120) intervals, 
during the initiation of antiarrhythmic drug therapy identifies patients at risk for proarrhythmia 
(Table 4). Amiodarone is more effective than other antiarrhythmic drugs (Table 4, 116,118) and can be 
used in patients with AF and reduced left ventricular function 119, but commonly causes extracardiac 
side effects.  Antiarrhythmic drugs can be combined with catheter ablation (“hybrid rhythm control 
therapy”) to reduce AF recurrences. 122  
Targeting triggers in, or close to, the pulmonary vein ostia has revolutionised AF ablation, 126 and 
isolation of the pulmonary veins is the accepted target of contemporary AF ablation procedures. 
127,128 When used in experienced centres, first-line ablation therapy is as safe and effective as 
antiarrhythmic drug therapy in selected patients 129,130. Catheter ablation is often the treatment of 
choice in AF patients who had recurrences on antiarrhythmic drug therapy. Catheter ablation is 
more effective than antiarrhythmic drug therapy in patients with paroxysmal 127 and chronic 
(persistent or long-standing persistent) AF. 128,132,133 Thus, the AF pattern is not considered a major 
factor in the decision for AF ablation. 2,128,134 Patients with recurrent AF despite initial ablation 
therapy should be discussed in a Rhythm Control AF Heart Team. More research is needed to guide 
the best method of catheter ablation beyond isolation of the pulmonary veins. 
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Table 4: Rhythm control therapy options in AF patients. All rhythm control interventions are 
clinically indicated to improve AF-related symptoms. Available data suggest an improvement in 
quality of life by rhythm control therapy. 
Rhythm control 
treatment 
Antiarrhythmic effect Unwanted effects ECG signs of 
unwanted effects 
Antiarrhythmic drugs 
Dronedarone 400 mg 
BD 
Doubling of sinus rhythm 
compared to placebo 
worsening of severe heart 
failure, torsades de points 
and/or heart block (rare) 
QT prolongation by 
> 60 ms on 
therapy, QT > 0.5 s, 
higher degree 
heart block 
Flecainide 100 – 150 
mg BD 
ventricular tachycardia in 
patients with prior myocardial 
infarction or heart failure, 
torsades de pointes (rare) 
Increase of QRS 
duration by >25% 
on therapy 
Propafenone 150 – 
300 mg TD  
ventricular tachycardia in 
patients with prior myocardial 
infarction or heart failure, 
torsades de pointes (rare) 
Increase of QRS 
duration by >25% 
on therapy 
Sotalol 160 mg BD torsades de pointes, heart 
block, accumulation in acute 
kidney failure, increased 
proarrhythmia risk in left 
ventricular hypertrophy and 
heart failure 
QT prolongation by 
> 60 ms on 
therapy, QT > 0.5 s, 
higher degree 
heart block 
Amiodarone 200mg 
OD (loading required 
over several weeks) 
More effective than other 
antiarrhythmic drugs in 
maintaining sinus rhythm 
High rate of extra-cardiac side 
effects (thyroid and liver 
dysfunction, light sensitivity, 
peripheral neuropathy), 
torsades de points and/or 
heart block (rare) 
QT > 0.5 s, higher 
degree heart block 
Interventional therapy 
Pulmonary vein 
isolation using 
cryoballoon or radio 
frequency energy 
Slightly more effective 
than antiarrhythmic drugs 
as first-line therapy, often 
requiring 2 or 3 
procedures, clearly more 
effective in patients who 
had recurrent AF on 
antiarrhythmic drugs 
periprocedural stroke, cardiac 
tamponade, oesophageal 
fistula, phrenic nerve palsy, 
brain white matter lesions, 
vascular damage, radiation 
exposure 
n.a. 
Additional ablation, 
e.g. linear lesions, 
ablation of specific 
electrogram 
patterns, etc. 
Effective for post-ablation 
tachycardias, effectiveness 
for AF unclear 
Same as pulmonary vein 
isolation, probably higher 
complication risk due to longer 
and less standardized 
procedures 
n.a. 
Surgical AF ablation Slightly more effective 
than catheter ablation 
Sinus node dysfunction, 
pneumothorax, cardiac 
tamponade, stroke 
n.a. 
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Integrated AF management, access to all therapy options, and the need to develop stratified AF 
therapy.  
The need for integration and differentiation of AF management. Implementation of the recent 
advances in AF management, e.g. access to medications that require specialist initiation or 
interventional and surgical therapy options, is not universal, as illustrated by the variable use of 
evidence-based treatments in recent observational data sets. 12,15,16,73,137 Furthermore, AF requires 
chronic management in a large population of patients, including provision of specialist treatment 
options when needed. Integrated, patient centred approaches to AF care are thus being developed 
to provide access to all forms of treatment and to ensure continuous management for all AF patients 
2,95,96, transferring concepts tested in other areas of medicine. 138-140  The size of the AF population 
calls for a staged approach to provide access to AF management for all patients. In fact, the first 
“nurse-led” models of integrated AF care were at least partially designed to cope with the sheer 
number of AF patients in need for advice and monitoring. 97  
Integrated AF care. Integrated AF care can be described as a care model that is open to all AF 
patients while providing an efficient infrastructure delivering care in all required treatment domains 
(Figure 3). Integrated AF care seems more timely now than ever, as more and more patients are in 
need for AF care (see section on AF screening above, and 1-3), while on the other hand subspecialist 
treatment options including stratified approaches to treatment are entering clinical practice. The 
best patterns of integrated AF care models will vary regionally, and there may be opportunities to 
merge integrated AF care services with other programmes, e.g. integrated heart failure and/or 
stroke care programmes. Even though the details of such integrated AF management programmes 
will vary locally and await optimisation by research 2,95,96, there is already a strong case underpinning 
integrated AF care programmes. Figure 3 outlines aspects of the current structure of AF care and the 
general structure of integrated AF care. A few key features of integrated AF care can be defined: 
1. The diagnosis of atrial fibrillation needs to be established by ECG before treatment can start. 
2. Integrated AF care provides easy access to AF care for all AF patients, close to where they 
live (Figure 3). Processes and infrastructures ensure that all patients in need for treatment in 
each of the five domains of AF care receive the care they need.  
3. Most initial management decisions can be made on the spot or after a few simple tests by 
general or acute physicians or experienced, specially trained nurses, including 
anticoagulation, antihypertensive therapy, life style advice, and initiation of rate control 
therapy. Regular follow-up visits that can also be performed locally, e.g. by nurses, 
pharmacists, general practitioners, and other health care professionals working within an 
integrated AF care framework.  
4. Integrated AF care requires good communication between all stake holders. Such 
communication will benefit from a common IT infrastructure, e.g. tools used by patients and 
health care professionals. The European Society of Cardiology, supported by the CATCH ME 
consortium (www.catch-me.eu), has provided two exemplary IT tools supporting integrated 
AF care for smartphones. They provide the essential knowledge to highlight AF management 
domains and to propose common solutions in line with evidence-based care.  
5. Specialist cardiology input and cardiac imaging (usually by transthoracic echocardiography) 
will be beneficial during the initiation of AF management in most patients. This can be 
provided remotely in collaborative teams.  
6. Shared decision making, putting the patient at the centre of the care process and involving 
families and carers, has the potential to increase adherence to chronic therapy. 141 Hence, 
shared decision making should be part of integrated care. Documenting this process will 
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benefit from a validated capture of patient-reported outcomes. 142,143 Adequately informed 
patients will be able to “own” the day-to-day management of AF, thereby ensuring 
adherence to chronic therapy.  
7. Patients who develop problems or complications on therapy and those who remain 
symptomatic should be managed with adequate specialist input, culminating in hospital care 
and multidisciplinary AF Heart Teams to guide and inform difficult management decisions in 
selected AF patients (Figure 3). Teamwork across disciplines and care boundaries can replace 
the current emphasis on triaging of patients. 
8. Integrated AF care programmes provide all AF patients access to research projects in AF, 
thus providing patients the choice to participate in such research projects and contributing 
to the further development of AF care. 
9. Integrated AF care structures allow to measure and improve quality of care 144 with a 
denominator that is reflecting the AF population. 
Stratified therapy of AF patients considering drivers of AF. Integrated AF care has the aim to render 
the best current AF therapy accessible for all AF patients in an efficient way. Even the best AF 
therapy, e.g. delivered in controlled clinical trials or in specialized centres, is only partially effective 
in preventing AF-related complications.2,11,12,72 Applying potentially effective therapies to large, 
unselected AF patient cohorts can completely avert expected treatment effects. 145-148 We currently 
do not have reliable methods to determine which AF patient will respond well to which therapy. This 
is particularly challenging for rate and rhythm control therapy. Hence, we are beginning to develop 
stratified or personalized approaches to AF therapy, and the tools to underpin such therapies are not 
available in full. 149 AF clinicians and researchers recognise that AF is caused by different disease 
drivers in different patients , and that these differences can be used to develop stratified approaches 
to AF management. 150 Unfortunately, different drivers for AF will overlap in individual patients 
144,150, and AF-inflicted damage will contribute common elements to cardiac dysfunction. 47,151-153 Still, 
a few examples exist where mechanism-based stratification of AF therapy has been successfully 
translated into clinical management:  
- Obese patients with AF benefit from structured weight reduction and fitness programmes, 
at times even obviating the need for scheduled AF ablation procedures. 61-63 It is not unlikely 
that fatty infiltration of the atria and activation of atrial adipocytes 59,60 mediate the 
“proarrhythmic” effect of obesity, and the antiarrhythmic effects of weight loss. 
- Sodium channel gene variants or mutations are not infrequent in patients with early-onset 
AF 154-158, and inherited arrhythmogenic diseases conveyed by sodium channel mutations 
include early-onset AF in their phenotype. 159-161 Sodium channel modulating ion channel 
blockers could be a promising treatment for such patients to prevent AF 162,163, similar to the 
effect of similar substances to prevent ventricular arrhythmias. The ESC AF guidelines 
suggest to actively assess the ECG and echocardiogram for such inherited conditions leading 
to AF, especially in young patients presenting with AF. Recent data furthermore suggest that 
common gene variants associated with AF can also modify the response to sodium channel 
blockers. 164  
- ACE inhibitors can prevent incident AF in patients with left ventricular hypertrophy 52 and 
those with markedly reduced left ventricular function 165, while the same treatment does not 
prevent recurrent AF in other patients. 147,148 This suggests that inhibition of the renin-
angiotensin system can prevent some forms of atrial cardiomyopathy 166, while the therapy 
seems without effect in patients without atrial damage mediated by activation of the renin-
angiotensin system. 
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Clearly, these examples can only illustrate how different types of AF, differentiated by the major 
pathophysiological drivers of the arrhythmia in individual patients, could potentially be used to 
develop personalised treatment concepts for atrial fibrillation in the future. 149 Ongoing research 
programmes will need to translate mechanistic insights into AF and its complications into clinical 
management concepts to unleash the full potential of personalized AF management. Integration of 
specialist knowledge and AF Heart Teams into clinical care will be the key to support these 
developments and to adjust them to clinical needs.  
 
In summary,  
I. Screening for silent AF emerges as an important opportunity to prevent AF-related 
complications.  
II. All AF patients should receive long-term treatment in five domains (Figure 2): 
1. Acute hemodynamic stabilization 
2. Detection and treatment of concomitant cardiovascular diseases 
3. Assessment of stroke risk and (in most patients) oral anticoagulation 
4. Assessment of ventricular rate and (in most patients) rate control therapy 
5. Assessment of symptoms related to AF and rhythm control therapy in those with AF-related 
symptoms. 
III. Successful AF management relies on integration of the following components (Figure 3) 
1. timely detection of AF (ideally prior to the first complication) 
2. provision of chronic support for the care of all AF patients, 
3. active patients who “own” their management,  
4. measurable quality of care,  
5. access to all treatment options for all AF patients, 
6. early identification and fast-track triaging of patients in need for specialist interventions, 
7. multidisciplinary AF Heart Teams informing difficult management decisions, and 
8. integration of clinical research projects into AF care programmes, e.g. developing stratified 
approaches to management. 
This can best be provided by integrated care provided by interdisciplinary and cross-sector health 
care teams including pharmacists, nurses, general physicians, and AF specialists (Figure 3). Difficult 
decisions will arise in some patients and should be guided by advice from AF Heart teams comprising 
specialists in stroke prevention, stroke therapy, rate and rhythm control therapy, interventional and 
surgical treatment of AF.  
IV. Future improvements will require a new taxonomy of AF identifying the major causes of 
AF in individual patients and the development and systematic evaluation of stratified AF 
therapy. 
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Search strategy. We searched the Cochrane Library (date range), MEDLINE (date range), and 
EMBASE (date range), supplemented by publications known to the author were necessary. We used 
the search terms “atrial fibrillation” combined with “stroke prevention”, “risk factor”, “rate control”, 
“rhythm control”, “anticoagulation”, “combination therapy”, “stroke”, “occluder”, “ablation”, or 
“surgery” where required. We largely selected publications in the past 6 years based on novelty, 
citations, and relevance for this clinical seminar, but did not exclude commonly referenced and 
highly regarded older publications. We also searched the reference lists of articles identified by this 
search strategy and selected those we judged relevant. Review articles and book chapters are cited 
to provide readers with more details and more references than this Seminar has room for. Our 
reference list was modified on the basis of comments from peer reviewers. 
Sources of funding. This seminar was written with supported by European Union (grant agreement 
No 633196 [CATCH ME]), British Heart Foundation (FS/13/43/30324), and Leducq Foundation. AFNET 
is partly funded by the DZHK (German Center for Cardiovascular Research) funded by BMBF. I would 
like to thank Dipak Kotecha for providing the CT image of the heart (Figure 1) and for help with 
preparing the figures. 
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Legends to Figures 
Figure 1: Main treatment options in the different domains of AF management and their cardiac 
targets. Shown is a CT image of a heart in an oblique and rotated view showing all four heart 
chambers, the pulmonary veins, the left atrial appendage, and the atrio-ventricular node. Boxes 
depict commonly used therapies and interventions in patients with atrial fibrillation. Arrows point to 
the main target of those therapies. Solid lines point to established treatment targets, dashed lines 
indicate potential additional treatment targets. AVN Atrio ventricular node, LA left atrium, LAA left 
atrial appendage, LV left ventricle. PV pulmonary veins, RA right atrium, RV right ventricle. CT image 
provided by Dr Dipak Kotecha, Birmingham. 
Figure 2: The five domains of AF management. AF patients require acute hemodynamic stabilization 
(depending on clinical presentation), detection treatment of concomitant cardiovascular conditions, 
stroke risk assessment and decision on oral anticoagulation therapy. These treatment domains have 
the potential to improve prognosis. Most AF patients also require rate control therapy, and those 
who are symptomatic will need rhythm control therapy to improve symptoms. Reproduced from 2, 
adapted from 167. 
Figure 3: Structure of Integrated AF Care (bottom panel) compared to current AF care (top panel). 
Current care models provide different access points for care, including no access, general practice / 
internists, office based cardiologists / cardiology outpatients, TIA and stroke services, emergency 
and acute medicine departments, and hospital-based cardiology and electrophysiology departments. 
Patients are often not put in contact with the team that can provide the best care for them, and 
follow-up is not structured across disciplines or sectors. Recently, many examples of better 
integration of AF care have been described. Integrated AF care (bottom panel) provides a common 
access point for all patients with AF, where initial assessment and therapy is delivered. The process 
of engaging and empowering patients is started here. Patients are then fast-tracked to receive 
appropriate further input into their treatment which may be continued in the community or 
supported by general practitioners, outpatient cardiologists, hospital-based specialties, or even AF 
Heart Teams providing input into difficult decisions and access to subspecialist interventions. 
Bringing health care professionals closer to the patient, ideally in the communities where they live, 
and working as a team supported by an IT infrastructure across disciplines and health care sectors 
are key components of integrated AF care. Such a service fulfils the quality criteria for a good AF 
service: Provision of all therapy options for all patients, measurable quality of care, multidisciplinary 
decision making when needed, and a service that is accessible to all AF patients. At the same time, 
reorganisation has the potential to manage more patients in the community, thus taking pressure 
off hospitals and specialist services. Integrated care will also allow to measure and improve quality 
of care across entire catchment areas.144 Furthermore, integrated AF care is conducive to innovation 
and research, e.g stratified therapy of AF patients. C counsellor, N nurse, O other health care 
professional, P physician, S specialist doctor. 
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